DeMedic
  • 📚Executive Summary
  • 📖Introduction
  • 🕶️The DeMedic Vision
  • 📀Core Features
    • Patient Data Ownership & Consent Control
    • DMEDI Token Utility
    • Peer-to-Peer Marketplace Architecture
    • Incentivized Participation Model
    • Researcher Access & Analytics Tools
    • Privacy, Encryption, and Compliance Standards
  • 🔧How It Works
    • Patient Onboarding and Data Contribution
    • Researcher Access Workflow
    • Data Privacy and Integrity Mechanisms
    • Ecosystem Flow: Data → Consent → Token → Utility
    • Incentive Alignment & Feedback Loop
  • 💰Tokenomics
    • Token Overview
    • Token Utility
    • Token Distribution
    • Economic Design Principles
    • Future Staking & DAO Features
  • 🖱️Use Cases
    • Clinical Research Acceleration
    • Real-World Evidence (RWE) for Drug Development
    • Public Health Surveillance & Crisis Response
    • AI Training for Health Diagnostics
    • Personalized Health Insights for Users
    • Ethical Monetization of Health Data
    • Medical Crowdsourcing & Patient-Led Research
  • 🏠Community & Governance
    • A Collaborative Community
    • Governance Model
    • Engagement Incentives
    • Open Ecosystem Philosophy
  • 🔐Security, Privacy & Compliance
    • Privacy by Design
    • End-to-End Encryption
    • Zero-Knowledge Proofs (ZKPs)
    • Differential Privacy
    • Identity & Access Management
    • Smart Contract Security
    • Data Sovereignty and User Controls
    • Regulatory Compliance
  • 🛣️Roadmap
    • Phase 1: Foundation & MVP (Q2 2025)
    • Phase 2: Early Ecosystem & Onboarding (Q3 2025)
    • Phase 3: Growth & Monetization (Q4 2025)
    • Phase 4: Decentralization & DAO Transition (Q1–Q2 2026)
    • Phase 5: Global Rollout & Institutional Adoption (Mid–Late 2026)
    • Ongoing: Innovation & Resilience
  • 📑Conclusion
Powered by GitBook
On this page
  1. Roadmap

Phase 5: Global Rollout & Institutional Adoption (Mid–Late 2026)

Objective: Expand DeMedic across borders and into clinical workflows.

Key Milestones:

  • Enterprise researcher plans and access licenses

  • Integration with EHR platforms and genomic testing services

  • Multilingual platform support and region-specific interfaces

  • DAO-curated grants for rare disease data collection

  • Launch of white-label platform for patient groups, NGOs, and nonprofits

  • Strategic partnerships with global health initiatives (WHO, academic alliances)

PreviousPhase 4: Decentralization & DAO Transition (Q1–Q2 2026)NextOngoing: Innovation & Resilience

Last updated 1 month ago

🛣️